Minimizing Liability with Export Control Compliance

Pharmaceutical Executive

Partner Eric McClafferty and senior associate Brooke Ringel co-authored the Pharmaceutical Executive article Minimizing Liability with Export Control Compliance.” The article discusses the significant legal and monetary risks that biopharmaceutical companies face for non-compliance with U.S. export control laws. The article goes on to discuss cost effective ways that organizations can build an export compliance component into an existing regulatory or biosecurity program.

To read full article, please click here.  Access may require subscription.